VIVIMEDLAB

Vivimed Labs Limited

Active pharmaceutical ingredients and formulations manufacturer

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹6.58
Market cap
55 Cr
Stock P/E
Loss (TTM EPS ₹-21.28)
ROCE (FY26)
-95.0%
Operating margin (FY26)
-253.5%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Vivimed Labs Limited is a pharmaceuticals company that is currently in a corporate insolvency resolution process.

Company snapshot

115thBy market cap

Ranked among 119 companies in Pharmaceuticals.

Segment mix

Reportable segments as of 2024-03-31 (Consolidated). Revenue share = segment revenue ÷ total revenue.

Largest segment: 91.6% of revenue

SegmentRevenue shareRevenuePBTAssets
Pharma Business
91.6%
35 Cr-9 Cr0 Cr
Speciality Chemicals Business
8.4%
3 Cr-25 Cr0 Cr

What we see

Concerns
  • ✗Net margin is negative — the company is spending more than it earns right now.
1 more signal from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricJun 2023Sept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Sales35 Cr34 Cr41 Cr39 Cr29 Cr25 Cr37 Cr26 Cr21 Cr21 Cr16 Cr12 Cr
Operating expenses (approx.)36 Cr40 Cr40 Cr67 Cr40 Cr25 Cr35 Cr28 Cr22 Cr22 Cr27 Cr151 Cr
EBITDA-0.33 Cr-6 Cr1 Cr-28 Cr-11 Cr-0.64 Cr1 Cr-2 Cr-0.28 Cr-0.95 Cr-11 Cr-139 Cr
OPM %-0.9%-17.5%3.1%-73.7%-37.4%-2.6%2.9%-7.8%-1.3%-4.6%-68.3%-1159.9%
Other income0.11 Cr2 Cr0.04 Cr8 Cr0.06 Cr0.03 Cr0.07 Cr4 Cr0.38 Cr0.21 Cr0 Cr6 Cr
Interest11 Cr12 Cr13 Cr-33 Cr0.30 Cr0.43 Cr0.48 Cr2 Cr0.58 Cr2 Cr1 Cr0.95 Cr
Depreciation5 Cr5 Cr5 Cr6 Cr4 Cr4 Cr7 Cr6 Cr5 Cr5 Cr5 Cr12 Cr
Profit before tax-16 Cr-20 Cr-17 Cr7 Cr-15 Cr-5 Cr-6 Cr-5 Cr-5 Cr-7 Cr-17 Cr-146 Cr
Tax %0.0%0.0%3.3%20.9%0.0%0.0%0.0%-2.2%0.0%0.0%0.0%-0.1%
Net profit-16 Cr-20 Cr-16 Cr5 Cr-15 Cr-5 Cr-6 Cr-5 Cr-5 Cr-7 Cr-17 Cr-146 Cr
EPS (₹)₹-1.88₹-2.45₹-1.24₹0.64₹-1.84₹-0.60₹-0.72₹-0.67₹-0.66₹-0.88₹-0.88₹-17.74

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,462 Cr1,186 Cr1,315 Cr1,059 Cr861 Cr237 Cr187 Cr149 Cr116 Cr70 CrSign in free for the trailing twelve months
Operating expenses (approx.)1,059 Cr974 Cr1,138 Cr1,051 Cr838 Cr245 Cr374 Cr182 Cr129 Cr221 CrSign in free for the trailing twelve months
EBITDA403 Cr212 Cr177 Cr8 Cr24 Cr-8 Cr-187 Cr-33 Cr-13 Cr-151 CrSign in free for the trailing twelve months
OPM %27.5%17.9%13.5%0.8%2.8%-3.4%-100.1%-22.4%-10.8%-216.2%Sign in free for the trailing twelve months
Other income8 Cr10 Cr23 Cr8 Cr10 Cr1 Cr0.97 Cr10 Cr4 Cr6 CrSign in free for the trailing twelve months
Interest66 Cr79 Cr67 Cr59 Cr54 Cr40 Cr36 Cr2 Cr3 Cr4 CrSign in free for the trailing twelve months
Depreciation58 Cr56 Cr67 Cr67 Cr55 Cr18 Cr108 Cr20 Cr20 Cr26 CrSign in free for the trailing twelve months
Profit before tax286 Cr88 Cr66 Cr-109 Cr-76 Cr-65 Cr-331 Cr-46 Cr-31 Cr-175 CrSign in free for the trailing twelve months
Tax %25.3%11.0%13.1%0.3%-2.7%-4.3%0.6%0.8%-0.4%-0.1%Sign in free for the trailing twelve months
Net profit214 Cr78 Cr57 Cr-109 Cr-78 Cr-68 Cr-329 Cr-45 Cr-31 Cr-175 CrSign in free for the trailing twelve months
EPS (₹)₹26.41₹18.44₹6.95₹-13.16₹-9.38₹-8.16₹-39.62₹-5.48₹-3.85₹-21.15Sign in free for the trailing twelve months
Dividend payout %——————————Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital16 Cr17 Cr17 Cr17 Cr17 Cr17 Cr17 Cr17 Cr17 Cr17 Cr
Reserves718 Cr1,210 Cr602 Cr493 Cr415 Cr348 Cr23 Cr-22 Cr-52 Cr-227 Cr
Borrowings835 Cr710 Cr757 Cr889 Cr253 Cr278 Cr379 Cr377 Cr847 Cr397 Cr
Other liabilities493 Cr445 Cr628 Cr486 Cr605 Cr623 Cr570 Cr579 Cr109 Cr567 Cr
Total liabilities2,062 Cr2,394 Cr2,329 Cr2,210 Cr1,289 Cr1,266 Cr988 Cr951 Cr921 Cr753 Cr
Fixed assets (net)652 Cr745 Cr662 Cr698 Cr348 Cr363 Cr278 Cr263 Cr254 Cr237 Cr
CWIP76 Cr65 Cr122 Cr89 Cr60 Cr40 Cr21 Cr21 Cr17 Cr18 Cr
Investments3 Cr3 Cr305 Cr86 Cr199 Cr199 Cr199 Cr168 Cr168 Cr181 Cr
Loans & advances——76 Cr79 Cr95 Cr100 Cr40 Cr41 Cr95 Cr21 Cr
Inventories484 Cr540 Cr564 Cr502 Cr256 Cr241 Cr80 Cr64 Cr59 Cr13 Cr
Trade receivables200 Cr275 Cr356 Cr249 Cr108 Cr87 Cr77 Cr83 Cr74 Cr45 Cr
Cash & bank55 Cr99 Cr95 Cr50 Cr6 Cr7 Cr4 Cr2 Cr0.21 Cr0.07 Cr
Other assets591 Cr666 Cr149 Cr456 Cr217 Cr230 Cr291 Cr309 Cr252 Cr239 Cr
Total assets2,062 Cr2,394 Cr2,329 Cr2,210 Cr1,289 Cr1,266 Cr988 Cr951 Cr921 Cr753 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity58 Cr21 Cr—80 Cr567 Cr-658 Cr14 Cr-24 Cr-11 Cr8 Cr
Cash from investing-68 Cr-164 Cr—-196 Cr404 Cr523 Cr-0.99 Cr28 Cr5 Cr-0.95 Cr
Cash from financing35 Cr186 Cr—72 Cr-1,015 Cr-10 Cr-16 Cr-6 Cr5 Cr-6 Cr
Net cash flow25 Cr44 Cr—-44 Cr-44 Cr-146 Cr-3 Cr-2 Cr-1 Cr0.65 Cr
Free cash flow (OCF − Capex)-11 Cr-142 Cr—-33 Cr567 Cr-658 Cr13 Cr-24 Cr-11 Cr8 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %22.5%8.6%7.8%-2.9%-3.2%-3.9%-70.5%-14.4%-4.0%-95.0%
ROE %29.1%6.3%6.1%-13.1%-18.0%-18.6%-833.4%———
Debtor days5085998645134149203232236
Inventory days311401365379261573264261370141
Days payable11515019117135100230180248589
Cash conversion cycle246336273294271607184284354-213
OCF / EBITDA %14.4%10.1%—n.m.n.m.—————
OCF / EBITDA % (3 years)—————n.m.————
Debt / equity1.140.581.221.750.590.769.600.00——
Current ratio1.341.621.381.271.551.360.780.830.800.37
Net debt / EBITDA1.94—3.74103.4410.35—————